Memory Loss Improvement Study With Prevagen Announced For Brain Awareness Week

Printer-friendly versionPDF version

Memory Loss Improvement Study QB-0011 - Prevagen Memory Study is being announced by Quincy Bioscience for Brain Awareness Week starting March 15th. Participants in the new study are ages 40-95 experiencing some memory loss.

Madison, WI - Memory Loss Improvement Study QB-0011 - Prevagen® Memory Study is being announced by Quincy Bioscience for Brain Awareness Week starting March 15th. The new Prevagen Memory Loss Study (http://prevagen.com/MemoryLoss.html) will evaluate the impact of Prevagen on cognitive function and other Quality of Life measures. Participants in the study are men and women between the ages of 40-95 experiencing some memory loss who will be using the brain health dietary supplement Prevagen.

Brain Awareness Week (http://www.dana.org/brainweek) is held every March and is a global campaign to increase public awareness about the progress and benefits of brain research. Brain Awareness Week (BAW) unites the efforts of universities, hospitals, patient groups, government agencies, schools, service organizations, and professional associations worldwide in a week-long celebration of the brain. Founded and coordinated by the Dana Alliance for Brain Initiatives and European Dana Alliance for the Brain, BAW is celebrating 15 years of education and outreach about the brain.

The new memory loss study, being announced for BAW by Quincy Biosciences, will use the brain health supplement Prevagen having as its main ingredient a naturally occurring calcium-binding protein discovered in jellyfish called apoaequorin. Prevagen is the first and only product to use this active ingredient.

The study is a randomized placebo-controlled, double-blind study that will require five cognitive testing sessions during the three-month study period. The impact of Prevagen on brain cell protection will be evaluated using computer-based cognitive testing software by Cogstate, Ltd., a leading cognitive testing software company based in Melbourne, Australia.

“We are excited about the new Prevagen Memory Study. We are researching various areas in order to bring hope to people with different health challenges related to aging and memory with the goal of improving quality of life,” says Mark Underwood, Quincy Bioscience president. “Additionally, we are doing a series of educational radio shows during March Brain Awareness Week to help raise brain awareness.”

Memory Loss (http://prevagen.com/MemoryLoss.html) Improvement Study with Prevagen is sponsored by Quincy Bioscience, (http://www.quincybioscience.com) a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms. Quincy Bioscience is developing health applications of the jellyfish protein apoaequorin for use in dietary supplements and pharmaceutical products. The company’s first product, Prevagen, was launched in the fall of 2007 and is intended to supplement the loss of critical calcium-binding proteins depleted in the normal course of healthy aging. * These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.